DOVATO 50 mg/300 mg, film-coated tablet 30 tablets, CIP 3400930280287
Active ingredients: Dolutegravir, Dolutegravir sodium, Lamivudine
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tablets, CIP 3400930280287orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DOVATO 50 mg/300 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette thermoformée PVC polychlortrifluoroéthylène avec sécurité enfant de 30 comprimés
- Marketing authorisation holder
- VIIV HEALTHCARE (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 16 Apr 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67301231CIP73028028CIP133400930280287Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LAMIVUDINEcomprimé | 300 mg · un comprimé | SA |
| DOLUTÉGRAVIR SODIQUEcomprimé | — | SA |
| DOLUTÉGRAVIRcomprimé | 50 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.